<DOC>
	<DOCNO>NCT02004028</DOCNO>
	<brief_summary>This open label neoadjuvant ( treatment VS-6063 prior mesothelioma surgery ) study subject malignant pleural mesothelioma eligible surgery . Subjects receive VS-6063 ( defactinib ) 400 mg twice daily 12 , 21 , 35 day . Pre- post-treatment biopsy blood sample collect . The purpose study ass biomarker response tumor tissue . The safety , pharmacokinetics , tumor response rate VS-6063 ( defactinib ) also assess .</brief_summary>
	<brief_title>Window Opportunity Study VS-6063 ( Defactinib ) Participants With Surgical Resectable Malignant Pleural Mesothelioma .</brief_title>
	<detailed_description />
	<mesh_term>Mesothelioma</mesh_term>
	<criteria>Histologically confirm malignant pleural mesothelioma metastatic unresectable Eligible undergo excisional surgery pleurectomy/decortication ( P/DC ) mesothelioma surgery . Localized disease . The malignancy confine one affected hemithorax . Mediastinal N2 lymph node via cervical mediastinoscopy EBUS ( endobronchial ultrasound ) must negative order eligible Grossly normal pulmonary , cardiac function , renal , hepatic hematologic performance function Male nonpregnant female Age â‰¥ 18 year age Tissue require prior enrollment . If patient diagnose outside tumor tissue available , pleural biopsy frozen tissue collection require . Participants chemotherapy radiotherapy time prior entering study prior time mesothelioma . Patients receive chemotherapy type drug benign condition participate trial History upper gastrointestinal bleeding , ulceration , perforation within 12 month prior first dose study drug Known history Gilbert 's Syndrome current hyperbilirubinemia cause Known history stroke cerebrovascular accident within 6 month prior first dose study drug Subjects know infection human immunodeficiency virus ( HIV ) Acquired Immune Deficiency Syndrome ( AIDS ) Subjects confirm Hepatitis A , B C Subjects actively treat secondary malignancy malignancy within last 3 year , exception nonmelanomatous skin cancer localize , definitively treated cervical cancer . Men observation local prostate cancer also eligible stable disease least 1 year . Uncontrolled severe cardiovascular disease , include myocardial infarct unstable angina within 6 month prior study treatment , New York Heart Association ( NYHA ) Class II great congestive heart failure , serious arrhythmia require medication treatment , clinically significant pericardial disease , cardiac amyloidosis Known history malignant hypertension Uncontrolled intercurrent illness include symptomatic congestive heart failure , cardiac arrhythmia , psychiatric illness/social situation opinion study investigator would associate undue risk participation study Use investigational drug within 28 day 5 halflives prior first dose . Pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Mesothelioma</keyword>
	<keyword>adenoma</keyword>
	<keyword>Neoplasms , Mesothelial</keyword>
	<keyword>Focal Adhesion Kinase Inhibitor</keyword>
</DOC>